Table 3 |
|||||
|
Neutralising antibody immune responses to homologous and heterologous H5N1 influenza strains following one or two doses of the AS03A-adjuvanted A/Indonesia/5/2005 (H5N1) influenza vaccine in terms of seropositivity rates and seroconversion rates. |
|||||
|
Antibody |
Time point |
N |
Seropositivity % (95% CI) |
N |
Seroconversion % (95% CI) |
|
|
|||||
|
A/Indonesia |
PRE |
99 |
11.1 (5.7-19.0) |
-- |
-- |
|
Day 42 |
100 |
100 (96.4-100) |
99 |
97.0 (91.4-99.4) |
|
|
Day 182 |
99 |
100 (96.3-100) |
98 |
93.9 (87.1-97.7) |
|
|
|
|||||
|
A/Vietnam |
PRE |
100 |
50.0 (39.8-60.2) |
-- |
-- |
|
Day 42 |
100 |
95.0 (88.7-98.4) |
100 |
47.0 (36.9-57.2) |
|
|
Day 182 |
99 |
92.9 (86.0-97.1) |
99 |
58.6 (48.2-68.4) |
|
|
|
|||||
|
Subjects received one dose of vaccine on Day 0 and one dose on Day 21 (ATP cohort for immunogenicity and persistence). Seroconversion rate for MN antibodies: Percentage of subjects with at least four-fold increase post-vaccination neutralising antibody titres. |
|||||
|
Nagai et al. BMC Infectious Diseases 2010 10:338 doi:10.1186/1471-2334-10-338 |
|||||
